


PHARMACEUTICAL 2020

Provention Bio Inc. Rank 189 of 362





PHARMACEUTICAL 2020

Provention Bio Inc. Rank 189 of 362

The relative strengths and weaknesses of Provention Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Provention Bio Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 3,319% points. The greatest weakness of Provention Bio Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 178% points.

The company's Economic Capital Ratio, given in the ranking table, is -190%, being 113% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,840
Liabilities, Non-Current	0
Other Assets	85,996
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,087
Property and Equipment	0
Research and Development	36,359
Revenues	0
Selling, General and Administrative Expense	8,013

Output Variable	Value in 1000 USD
Assets	85,996
Liabilities	3,840
Expenses	44,372
Stockholders Equity	82,156
Net Income	-43,285
Comprehensive Net Income	-43,285
Economic Capital Ratio	-190%